Submitted:
01 February 2025
Posted:
03 February 2025
You are already at the latest version
Abstract
Keywords:
Introduction
Materials and Methods
Questionnaires
| OF-5 specific questions |
|
| |
| Questions common to OF-5 and OFI-8 |
|
| |
| |
| OFI-8 specific questions |
|
| |
| |
| |
|
Statistical Analysis
Results
Participant Characteristics and Findings
Oral Frailty and Functional Differences
OF-5 and OFI-8 Scoring Analysis
Discussion
Conclusion
Author Contributions
Sources of Financial Support That Require Acknowledgment
Approval Code Issued by the Institutional Review Board (IRB) and the Name of the Institution(s) that Granted the Approval
Acknowledgements
Conflicts of interest
References
- Tanaka, T.; Takahashi, K.; Hirano, H.; et al. Oral Frailty as a Risk Factor for Physical Frailty and Mortality in Community-Dwelling Elderly. J Gerontol A Biol Sci Med Sci. 2018, 73, 1661–1667. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, T.; Hirano, H.; Ikebe, K.; et al. Oral frailty five-item checklist to predict adverse health outcomes in community-dwelling older adults: A Kashiwa cohort study. Geriatr Gerontol Int. 2023, 23, 651–659. [Google Scholar] [CrossRef] [PubMed]
- Iwasaki, M.; Shirobe, M.; Motokawa, K.; et al. Validation of self-reported articulatory oral motor skill against objectively measured repetitive articulatory rate in community-dwelling older Japanese adults: The Otassha Study. Geriatr Gerontol Int. 2023, 23, 729–735. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, T.; Hirano, H.; Ikebe, K.; et al. Consensus statement on “Oral frailty” from the Japan Geriatrics Society, the Japanese Society of Gerodontology, and the Japanese Association on Sarcopenia and Frailty. Geriatr Gerontol Int. 2024, 24, 1111–1119. [Google Scholar] [CrossRef] [PubMed]
- Kusunoki, H.; Hasegawa, Y.; Nagasawa, Y.; et al. Oral Frailty and Its Relationship with Physical Frailty in Older Adults: A Longitudinal Study Using the Oral Frailty Five-Item Checklist. Nutrients. 2024, 17, 17. [Google Scholar] [CrossRef]
- Tanaka, T.; Hirano, H.; Ohara, Y.; et al. Oral Frailty Index-8 in the risk assessment of new-onset oral frailty and functional disability among community-dwelling older adults. Arch Gerontol Geriatr. 2021, 94, 104340. [Google Scholar] [CrossRef]
- Kusunoki, H.; Ekawa, K.; Kato, N.; et al. Association between oral frailty and cystatin C-related indices-A questionnaire (OFI-8) study in general internal medicine practice. PLoS One. 2023, 18, e0283803. [Google Scholar] [CrossRef] [PubMed]
- Miyahara, S.; Maeda, K.; Kawamura, K.; et al. Concordance in oral frailty five-item checklist and oral hypofunction: Examining their respective characteristics. Arch Gerontol Geriatr. 2024, 118, 105305. [Google Scholar] [CrossRef] [PubMed]
- Iwasaki, M.; Shirobe, M.; Motokawa, K.; et al. Prevalence of oral frailty and its association with dietary variety, social engagement, and physical frailty: Results from the Oral Frailty 5-Item Checklist. Geriatr Gerontol Int. 2024, 24, 371–377. [Google Scholar] [CrossRef]
- Minakuchi, S.; Tsuga, K.; Ikebe, K.; et al. Oral hypofunction in the older population: Position paper of the Japanese Society of Gerodontology in 2016. Gerodontology. 2018, 35, 317–324. [Google Scholar] [CrossRef] [PubMed]


| Total (n = 270) |
Men (n = 133) |
Women (n = 137) |
p | ||
|---|---|---|---|---|---|
| Age (years) | 77.6±7.3 | 77.0±7.5 | 78.3±7.1 | 0.143 | |
| Height (cm) | 158.1±9.1 | 164.8±6.8 | 151.7±5.9 | <0.001 | |
| Weight (kg) | 59.6±11.8 | 66.1±10.7 | 53.2±9.0 | <0.001 | |
| Body mass index: BMI | 23.7±3.4 | 24.3±3.1 | 23.1±3.5 | 0.003 | |
| Grip strength (kg) | 23.0±8.8 | 29.5±7.1 | 16.6±4.4 | <0.001 | |
| White blood cells (/μL) | 5875±1574 | 5986±1596 | 5767±1551 | 0.255 | |
| Red blood cells (×104/μL) | 426±52 | 435±57 | 417±45 | 0.004 | |
| Hemoglobin (g/dL) | 13.2±1.6 | 13.7±1.6 | 12.8±1.4 | <0.001 | |
| Hematocrit (%) | 39.8±4.6 | 41.0±4.6 | 38.7±4.3 | <0.001 | |
| Platelets(×104/μL) | 21.3±5.1 | 20.5±4.8 | 22.1±5.3 | 0.007 | |
| Total protein (g/dL) | 7.0±0.4 | 7.0±0.4 | 7.1±0.4 | 0.140 | |
| Albumin (g/dL) | 4.1±0.4 | 4.2±0.4 | 4.1±0.4 | 0.793 | |
| Creatine (mg/dL) | 0.95±0.40 | 1.09±0.46 | 0.82±0.28 | <0.001 | |
| Hypertension, n(%) | 232(85.9) | 118(88.7) | 114(83.2) | 0.223 | |
| Comorbidities | |||||
| Diabetes, n(%) | 60(22.2) | 34(25.6) | 26(19.0) | 0.241 | |
| Dyslipidemia, n(%) | 148(54.8) | 66(49.6) | 82(59.9) | 0.112 | |
| Osteoporosis, n(%) | 20(7.4) | 5(3.8) | 15(10.9) | 0.035 | |
| Malignant neoplasm, n(%) | 23(8.5) | 16(12.0) | 7(5.1) | 0.005 | |
| Cardiovascular disease, n(%) | 71(26.3) | 41(30.8) | 30(21.9) | 0..100 | |
| Cerebrovascular disease, n(%) | 30(11.1) | 14(10.5) | 16(11.7) | 0.847 | |
| Questions | |||||
| OF-5 specific questions |
|
90(33.3) | 35(26.3) | 55(40.1) | 0.020 |
|
31(11.5) | 20(15.0) | 11(8.0) | 0.086 | |
| Questions common to OFI-5 and OFI-8 |
|
56(20.7) | 19(14.3) | 37(27.0) | 0.011 |
|
75(27.8) | 34(25.6) | 41(29.9) | 0.497 | |
|
101(37.4) | 46(34.6) | 55(40.1) | 0.380 | |
| OFI-8 specific questions |
|
156(57.8) | 75(56.4) | 81(59.1) | 0.712 |
|
76(28.1) | 28(21.1) | 48(35.0) | 0.015 | |
|
38(14.1) | 13(9.7) | 25(18.2) | 0.054 | |
|
57(21.1) | 32(24.1) | 25(18.2) | 0.297 | |
|
55(20.4) | 25(18.8) | 30(21.9) | 0.549 | |
| Questionnaire score results | |||||
| OF-5 score | 1.3±1.1 | 1.2±1.1 | 1.5±1.0 | 0.025 | |
| Oral frailty, ≥2 OF-5 score, n(%) | 110(40.7) | 45(33.8) | 65(47.4) | 0.016 | |
| OFI-8 score | 3.3±2.1 | 3.0±2.0 | 3.7±2.2 | 0.012 | |
| OFI-8 score≦2, n(%) | 107(39.6) | 61(45.9) | 46(33.6) | 0.047 | |
| OFI-8 score=3, n(%) | 42(15.6) | 21(15.8) | 21(15.3) | 1.000 | |
| OFI-8 score≧4, n(%) | 121(44.8) | 51(38.3) | 70(51.1) | 0.038 | |
| Men (n = 133) | Women (n = 137) | |||||
|---|---|---|---|---|---|---|
| Oral non-frailty, 0–1 OF-5 score (n = 88) |
Oral frailty, ≥2 OF-5 score (n = 45) |
p | Oral non-frailty, 0–1 OF-5 score (n = 72) |
Oral frailty, ≥2 OF-5 score (n = 65) |
p | |
| Age (year-old) | 75.9±7.4 | 79.1±7.5 | 0.021 | 78.0±7.1 | 78.6±7.1 | 0.673 |
| Height (cm) | 165.4±7.2 | 163.5±5.9 | 0.131 | 151.9±5.0 | 151.5±6.8 | 0.701 |
| Body weight (kg) | 67.3±11.5 | 63.9±8.6 | 0.088 | 53.9±9.1 | 52.4±8.9 | 0.328 |
| Body mass index | 24.5±3.2 | 23.9±2.9 | 0.300 | 23.3±3.7 | 22.8±3.3 | 0.360 |
| Grip strength (kg) | 30.2±7.0 | 28.1±7.3 | 0.114 | 17.0±4.1 | 16.1±4.8 | 0.248 |
| White blood cells (/μL) | 5769±1405 | 6410±1859 | 0.028 | 5663±1525 | 5884±1584 | 0.408 |
|
Red blood cells (×104/μL) |
438±59 | 429±54 | 0.414 | 419±42 | 415±49 | 0.590 |
| Hemoglobin (g/dL) | 13.8±1.7 | 13.5±1.4 | 0.404 | 12.8±1.5 | 12.7±1.4 | 0.702 |
| Hematocrit (%) | 41.3±4.9 | 40.5±4.0 | 0.327 | 38.7±4.3 | 38.6±4.3 | 0.900 |
| Platelets (×104/μL) | 20.5±5.0 | 20.5±4.5 | 0.981 | 22.3±5.2 | 22.1±5.4 | 0.846 |
| Total protein (g/dL) | 7.0±0.4 | 7.0±0.5 | 0.931 | 7.1±0.4 | 7.1±0.4 | 0.957 |
| Albumin (g/dL) | 4.2±0.4 | 4.1±0.4 | 0.375 | 4.2±0.4 | 4.1±0.3 | 0.767 |
| Creatinine (mg/dL) | 1.12±0.52 | 1.03±0.30 | 0.299 | 0.83±0.22 | 0.82±0.33 | 0.870 |
| Hypertension, n(%) | 79(89.8) | 39(86.7) | 0.576 | 64(88.9) | 50(76.9) | 0.070 |
| Diabetes, n(%) | 22(25.0) | 12(26.7) | 0.836 | 11(15.3) | 15(23.1) | 0.280 |
| Dyslipidemia, n(%) | 45(51.1) | 21(46.7) | 0.715 | 47(65.3) | 35(53.8) | 0.222 |
| Osteoporosis, n(%) | 5(5.7) | 0(0.0) | 0.167 | 5(6.9) | 10(15.4) | 0.170 |
| Malignant neoplasm, n(%) | 10(11.4) | 6(13.3) | 0.782 | 3(4.2) | 4(6.2) | 0.708 |
| Cardiovascular disease, n(%) | 28(31.8) | 13(28.9) | 0.843 | 17(23.6) | 13(20.0) | 0.682 |
| Cerebrovascular disease, n(%) | 8(9.1) | 6(13.3) | 0.552 | 9(12.5) | 7(10.8) | 0.796 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).